-
1
-
-
4944249117
-
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
-
S.M. Wilhelm, C. Carter, and L. Tang BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109
-
(2004)
Cancer Res
, vol.64
, pp. 7099-7109
-
-
Wilhelm, S.M.1
Carter, C.2
Tang, L.3
-
2
-
-
47049094020
-
Metastatic melanoma: Scientific rationale for sorafenib treatment and clinical results
-
F. Egberts, K.C. Kahler, and E. Livingstone Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results Onkologie 31 2008 398 403
-
(2008)
Onkologie
, vol.31
, pp. 398-403
-
-
Egberts, F.1
Kahler, K.C.2
Livingstone, E.3
-
3
-
-
33846260566
-
Sorafenib for the treatment of advanced renal cell carcinoma
-
R.C. Kane, A.T. Farrell, and H. Saber Sorafenib for the treatment of advanced renal cell carcinoma Clin Cancer Res 12 2006 7271 7278
-
(2006)
Clin Cancer Res
, vol.12
, pp. 7271-7278
-
-
Kane, R.C.1
Farrell, A.T.2
Saber, H.3
-
4
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
J.M. Llovet, S. Ricci, and V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
-
(2008)
N Engl J Med
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
-
5
-
-
33846212284
-
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
-
L. Liu, Y. Cao, and C. Chen Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Res 66 2006 11851 11858
-
(2006)
Cancer Res
, vol.66
, pp. 11851-11858
-
-
Liu, L.1
Cao, Y.2
Chen, C.3
-
6
-
-
39149129114
-
Mutant FLT3: A direct target of sorafenib in acute myelogenous leukemia
-
W. Zhang, M. Konopleva, and Y.X. Shi Mutant FLT3: A direct target of sorafenib in acute myelogenous leukemia J Natl Cancer Inst 100 2008 184 198
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 184-198
-
-
Zhang, W.1
Konopleva, M.2
Shi, Y.X.3
-
7
-
-
52749099497
-
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: A systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
-
H. Linardou, I.J. Dahabreh, and D. Kanaloupiti Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: A systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer Lancet Oncol 9 2008 962 972
-
(2008)
Lancet Oncol
, vol.9
, pp. 962-972
-
-
Linardou, H.1
Dahabreh, I.J.2
Kanaloupiti, D.3
-
8
-
-
38049019119
-
Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: A review of clinical trials
-
C.H. Takimoto, and A. Awada Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: A review of clinical trials Cancer Chemother Pharmacol 61 2008 535 548
-
(2008)
Cancer Chemother Pharmacol
, vol.61
, pp. 535-548
-
-
Takimoto, C.H.1
Awada, A.2
-
9
-
-
51049098909
-
Selected combination therapy with sorafenib: A review of clinical data and perspectives in advanced solid tumors
-
L. Dal Lago, V. D'Hondt, and A. Awada Selected combination therapy with sorafenib: A review of clinical data and perspectives in advanced solid tumors Oncologist 13 2008 845 858
-
(2008)
Oncologist
, vol.13
, pp. 845-858
-
-
Dal Lago, L.1
D'Hondt, V.2
Awada, A.3
-
10
-
-
34250218226
-
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab
-
D. Curran, J. Giralt, and P.M. Harari Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab J Clin Oncol 25 2007 2191 2197
-
(2007)
J Clin Oncol
, vol.25
, pp. 2191-2197
-
-
Curran, D.1
Giralt, J.2
Harari, P.M.3
-
11
-
-
32144433159
-
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
-
J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578
-
(2006)
N Engl J Med
, vol.354
, pp. 567-578
-
-
Bonner, J.A.1
Harari, P.M.2
Giralt, J.3
-
12
-
-
34748831698
-
Biology of interactions: Antiepidermal growth factor receptor agents
-
P.M. Harari, G.W. Allen, and J.A. Bonner Biology of interactions: Antiepidermal growth factor receptor agents J Clin Oncol 25 2007 4057 4065
-
(2007)
J Clin Oncol
, vol.25
, pp. 4057-4065
-
-
Harari, P.M.1
Allen, G.W.2
Bonner, J.A.3
-
13
-
-
35148842941
-
Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation
-
J.P. Plastaras, S.H. Kim, and Y.Y. Liu Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation Cancer Res 67 2007 9443 9454
-
(2007)
Cancer Res
, vol.67
, pp. 9443-9454
-
-
Plastaras, J.P.1
Kim, S.H.2
Liu, Y.Y.3
-
14
-
-
33748676449
-
Chemotherapy with preoperative radiotherapy in rectal cancer
-
J.F. Bosset, L. Collette, and G. Calais Chemotherapy with preoperative radiotherapy in rectal cancer N Engl J Med 355 2006 1114 1123
-
(2006)
N Engl J Med
, vol.355
, pp. 1114-1123
-
-
Bosset, J.F.1
Collette, L.2
Calais, G.3
-
15
-
-
33750580102
-
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203
-
J.P. Gerard, T. Conroy, and F. Bonnetain Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203 J Clin Oncol 24 2006 4620 4625
-
(2006)
J Clin Oncol
, vol.24
, pp. 4620-4625
-
-
Gerard, J.P.1
Conroy, T.2
Bonnetain, F.3
-
16
-
-
6044226542
-
Preoperative versus postoperative chemoradiotherapy for rectal cancer
-
R. Sauer, H. Becker, and W. Hohenberger Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med 351 2004 1731 1740
-
(2004)
N Engl J Med
, vol.351
, pp. 1731-1740
-
-
Sauer, R.1
Becker, H.2
Hohenberger, W.3
-
17
-
-
70449726857
-
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03
-
M.S. Roh, L.H. Colangelo, and M.J. O'Connell Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03 J Clin Oncol 27 2009 5124 5130
-
(2009)
J Clin Oncol
, vol.27
, pp. 5124-5130
-
-
Roh, M.S.1
Colangelo, L.H.2
O'Connell, M.J.3
-
18
-
-
64649083998
-
Phase i trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients
-
L. Ugidos, S. Delgado, and C. Conill Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients Invest New Drugs 27 2009 262 268
-
(2009)
Invest New Drugs
, vol.27
, pp. 262-268
-
-
Ugidos, L.1
Delgado, S.2
Conill, C.3
-
19
-
-
34648814228
-
Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group
-
G.A. Hospers, C.J. Punt, and M.E. Tesselaar Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group Ann Surg Oncol 14 2007 2773 2779
-
(2007)
Ann Surg Oncol
, vol.14
, pp. 2773-2779
-
-
Hospers, G.A.1
Punt, C.J.2
Tesselaar, M.E.3
-
20
-
-
67149086939
-
Molecular targeted treatment and radiation therapy for rectal cancer
-
F. Marquardt, F. Rodel, and G. Capalbo Molecular targeted treatment and radiation therapy for rectal cancer Strahlenther Onkol 185 2009 371 378
-
(2009)
Strahlenther Onkol
, vol.185
, pp. 371-378
-
-
Marquardt, F.1
Rodel, F.2
Capalbo, G.3
-
21
-
-
0142011609
-
Reduced survival of rectal cancer patients with increased tumor epidermal growth factor receptor levels
-
R. Kopp, E. Rothbauer, and E. Mueller Reduced survival of rectal cancer patients with increased tumor epidermal growth factor receptor levels Dis Colon Rectum 46 2003 1391 1399
-
(2003)
Dis Colon Rectum
, vol.46
, pp. 1391-1399
-
-
Kopp, R.1
Rothbauer, E.2
Mueller, E.3
-
22
-
-
34547445551
-
Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
-
F. Bertolini, C. Bengala, and L. Losi Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy Int J Radiat Oncol Biol Phys 68 2007 1455 1461
-
(2007)
Int J Radiat Oncol Biol Phys
, vol.68
, pp. 1455-1461
-
-
Bertolini, F.1
Bengala, C.2
Losi, L.3
-
23
-
-
18344388638
-
An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation
-
S. Cascinu, F. Graziano, and V. Catalano An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation Br J Cancer 86 2002 744 749
-
(2002)
Br J Cancer
, vol.86
, pp. 744-749
-
-
Cascinu, S.1
Graziano, F.2
Catalano, V.3
-
24
-
-
34247848005
-
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase i trial results
-
B.G. Czito, J.C. Bendell, and C.G. Willett Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results Int J Radiat Oncol Biol Phys 68 2007 472 478
-
(2007)
Int J Radiat Oncol Biol Phys
, vol.68
, pp. 472-478
-
-
Czito, B.G.1
Bendell, J.C.2
Willett, C.G.3
-
25
-
-
11144354392
-
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
-
C.G. Willett, Y. Boucher, and E. di Tomaso Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 2004 145 147
-
(2004)
Nat Med
, vol.10
, pp. 145-147
-
-
Willett, C.G.1
Boucher, Y.2
Di Tomaso, E.3
-
26
-
-
33750360895
-
Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: Theory and clinical practice
-
C.G. Willett, S.V. Kozin, and D.G. Duda Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice Semin Oncol 33 2006 S35 S40
-
(2006)
Semin Oncol
, vol.33
-
-
Willett, C.G.1
Kozin, S.V.2
Duda, D.G.3
-
27
-
-
59949091448
-
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
-
C. Bokemeyer, I. Bondarenko, and A. Makhson Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 2009 663 671
-
(2009)
J Clin Oncol
, vol.27
, pp. 663-671
-
-
Bokemeyer, C.1
Bondarenko, I.2
Makhson, A.3
-
28
-
-
63849088630
-
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
-
E. Van Cutsem, C.H. Kohne, and E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
-
(2009)
N Engl J Med
, vol.360
, pp. 1408-1417
-
-
Van Cutsem, E.1
Kohne, C.H.2
Hitre, E.3
-
29
-
-
64049090889
-
Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR
-
V. Heinemann, S. Stintzing, and T. Kirchner Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR Cancer Treat Rev 35 2009 262 271
-
(2009)
Cancer Treat Rev
, vol.35
, pp. 262-271
-
-
Heinemann, V.1
Stintzing, S.2
Kirchner, T.3
-
30
-
-
42149083899
-
Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers
-
L. Barault, N. Veyrie, and V. Jooste Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers Int J Cancer 122 2008 2255 2259
-
(2008)
Int J Cancer
, vol.122
, pp. 2255-2259
-
-
Barault, L.1
Veyrie, N.2
Jooste, V.3
-
31
-
-
55049136730
-
Targeted therapies for metastatic renal cell carcinoma: An overview of toxicity and dosing strategies
-
T.E. Hutson, R.A. Figlin, and J.G. Kuhn Targeted therapies for metastatic renal cell carcinoma: An overview of toxicity and dosing strategies Oncologist 13 2008 1084 1096
-
(2008)
Oncologist
, vol.13
, pp. 1084-1096
-
-
Hutson, T.E.1
Figlin, R.A.2
Kuhn, J.G.3
-
32
-
-
0034084314
-
Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis
-
S.M. Huang, and P.M. Harari Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis Clin Cancer Res 6 2000 2166 2174
-
(2000)
Clin Cancer Res
, vol.6
, pp. 2166-2174
-
-
Huang, S.M.1
Harari, P.M.2
-
33
-
-
18044387648
-
Raf kinase as a target for anticancer therapeutics
-
S.S. Sridhar, D. Hedley, and L.L. Siu Raf kinase as a target for anticancer therapeutics Mol Cancer Ther 4 2005 677 685
-
(2005)
Mol Cancer Ther
, vol.4
, pp. 677-685
-
-
Sridhar, S.S.1
Hedley, D.2
Siu, L.L.3
-
34
-
-
33748063941
-
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance
-
J.A. McCubrey, L.S. Steelman, and S.L. Abrams Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance Adv Enzyme Regul 46 2006 249 279
-
(2006)
Adv Enzyme Regul
, vol.46
, pp. 249-279
-
-
McCubrey, J.A.1
Steelman, L.S.2
Abrams, S.L.3
-
35
-
-
16644397086
-
The role of Raf-1 in radiation resistance of human hepatocellular carcinoma Hep G2 cells
-
W.Y. Tang, S.P. Chau, and W.P. Tsang The role of Raf-1 in radiation resistance of human hepatocellular carcinoma Hep G2 cells Oncol Rep 12 2004 1349 1354
-
(2004)
Oncol Rep
, vol.12
, pp. 1349-1354
-
-
Tang, W.Y.1
Chau, S.P.2
Tsang, W.P.3
|